Skip to main content
. 2015 Sep 22;67(10):1354–1362. doi: 10.1002/acr.22598

Figure 2.

Figure 2

Efficacy evaluation by disease activity category in patients who switched from intravenous to subcutaneous tocilizumab (TCZ IV/SC) and who continued TCZ‐SC. A, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR), and B, Clinical Disease Activity Index (CDAI) score.